Начало・Списък с акции・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

4.38 8.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.03

Максимум

4.43

Ключови измерители
By Trading Economics
Приходи	11M 51M
Продажби	6.5M 113M
P/E Средно за сектора	4.553 51.78
EPS	0.31
Марж на печалбата	45.374
Служители	100
EBITDA	6.6M 81M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+48.88% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-156M 572M
Предишно отваряне	-4.3
Предишно затваряне	4.38

Ironwood Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.11.2026 г., 22:41 ч. UTC

Ironwood Pharmaceuticals, Inc. shares declined in after-market trading, reaching their lowest level since Friday's close following a sharp retracement from earlier gains.

5.11.2026 г., 21:04 ч. UTC

News

Ironwood Pharmaceuticals reported a 49% year-over-year increase in Q3 net income to $59.8 million and raised its 2026 revenue guidance to $485 million-$510 million.

4.11.2026 г., 23:16 ч. UTC

Ironwood Pharmaceuticals, Inc. is trading higher in after-market hours, maintaining a position above its 20-day moving average despite a recent decline from an early high.

3.11.2026 г., 21:07 ч. UTC

Ironwood Pharmaceuticals, Inc. is trading higher, having gained since Monday's close, despite retracing from an early session peak.

2.11.2026 г., 23:06 ч. UTC

Ironwood Pharmaceuticals, Inc. traded modestly higher in after-market hours following Monday's close amid mixed broader market signals and economic data.

30.10.2026 г., 22:56 ч. UTC

Ironwood Pharmaceuticals, Inc. shares are trading modestly higher in after-market hours, improving from earlier levels but remaining below their 20-day moving average.

28.10.2026 г., 19:46 ч. UTC

Ironwood Pharmaceuticals, Inc. is trading higher, having peaked in late trading.

26.10.2026 г., 19:46 ч. UTC

Ironwood Pharmaceuticals Inc is trading roughly flat, showing little significant movement since Friday's close and remaining below its 20-day moving average.

23.10.2026 г., 21:26 ч. UTC

Ironwood Pharmaceuticals Inc shares advanced modestly during after-market hours on Friday, reaching a peak return since Friday's close.

22.10.2026 г., 19:46 ч. UTC

Ironwood Pharmaceuticals Inc is trading roughly flat, remaining below its 20-day moving average and near the lower end of its one-month range.

21.10.2026 г., 22:26 ч. UTC

Ironwood Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase from its earlier low since Wednesday's close.

16.10.2026 г., 19:51 ч. UTC

News

Ironwood Pharmaceuticals announces Tammi Gaskins will succeed Tom McCourt as CEO effective January 1, 2027, raising investor concerns about the company's future direction.

15.10.2026 г., 20:07 ч. UTC

Ironwood Pharmaceuticals Inc shares are advancing, peaking around midday amid a broader market rise, though still below its 20-day moving average.

14.10.2026 г., 20:07 ч. UTC

Ironwood Pharmaceuticals Inc shares are modestly higher.

13.10.2026 г., 22:31 ч. UTC

Ironwood Pharmaceuticals Inc is trading modestly higher in after-market hours, recovering from a low earlier in the session after three consecutive declines.

12.10.2026 г., 21:01 ч. UTC

Ironwood Pharmaceuticals Inc shares advanced in after-market trading following Monday's close, maintaining stability.

8.10.2026 г., 20:07 ч. UTC

Ironwood Pharmaceuticals Inc shares are advancing, recovering from earlier losses, but remain 4.66% below their 20-day moving average.

7.10.2026 г., 23:00 ч. UTC

Ironwood Pharmaceuticals Inc is down significantly in after-market trading, falling sharply from earlier gains and currently below its 20-day moving average.

6.10.2026 г., 19:35 ч. UTC

Ironwood Pharmaceuticals Inc is trading roughly flat, remaining below its 20-day moving average and near the lower end of its one-month range.

5.10.2026 г., 22:25 ч. UTC

Ironwood Pharmaceuticals Inc. is trading modestly higher in after-market hours, maintaining a cumulative return after initially peaking earlier in the session.

2.10.2026 г., 23:55 ч. UTC

Ironwood Pharmaceuticals Inc's shares traded roughly flat in after-market hours, following recent lower closes amid broader market trends in labor force engagement and wage growth.

1.10.2026 г., 22:01 ч. UTC

Ironwood Pharmaceuticals Inc is trading modestly lower in after-market hours, marking a fourth consecutive session of decline and remaining below its 20-day moving average.

24.09.2026 г., 19:25 ч. UTC

Ironwood Pharmaceuticals Inc shares fell sharply, retracing from an initial peak and remaining below the previous close and 20-day moving average.

18.09.2026 г., 20:02 ч. UTC

Ironwood Pharmaceuticals Inc is advancing, continuing a higher trend since Thursday's close, despite currently trading lower in today's market.

17.09.2026 г., 20:08 ч. UTC

Ironwood Pharmaceuticals Inc is advancing, reflecting broader market gains, despite earlier pulling back amid profit-taking during Thursday's trading session.

16.09.2026 г., 23:51 ч. UTC

Ironwood Pharmaceuticals Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and around the midpoint of its one-month trading range.

15.09.2026 г., 22:11 ч. UTC

Ironwood Pharmaceuticals shares are lower in after-market trading, reflecting volatility amid broader market caution as Treasury yields rise. No specific news was identified.

14.09.2026 г., 23:16 ч. UTC

Ironwood Pharmaceuticals Inc's shares are lower in after-market hours, with no specific news identified to explain the decline. The stock is below its 20-day moving average.

11.09.2026 г., 21:01 ч. UTC

Ironwood Pharmaceuticals shares are lower in after-market hours, continuing a decline since Friday's close and trading well below the 20-day moving average.

1.09.2026 г., 19:46 ч. UTC

Ironwood Pharmaceuticals Inc is trading higher, recovering from earlier session lows while remaining above its 20-day moving average. No specific news was identified.

Сравнение с други в отрасъла

Ценова промяна

Ironwood Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

48.88% нагоре

12-месечна прогноза

Среден 6 USD 48.88%

Висок 6 USD

Нисък 6 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Ironwood Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Ironwood Pharmaceuticals Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.